This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakamoto, T. Articles by Chodak, G. W. Search for Related Content PubMed PubMed Citation Articles by Nakamoto, T. Articles by Chodak, G. W.

Basic Fibroblast Growth Factor in Human Prostate Cancer Cells¹

Department of Surgery, Section of Urology, The University of Chicago, and Pritzker School of Medicine, Chicago, Illinois 60637

To increase our understanding of the potential role of basic fibroblast growth factor (bFGF) in malignant progression of prostate cancer, we determined the production of bFGF, the expression of FGF receptor (flg), and the response to exogenous bFGF in LNCaP, DU 145, and PC 3 cells. We observed that these three prostate cancer cell lines, which differed in their dependence on androgens for growth in vitro and in their in vivo behavior in nude mice, could be distinguished as follows: (a) androgen-sensitive LNCaP cells, which do not metastasize in nude mice, did not produce measurable amounts of bFGF, expressed small but measurable amounts of FGF receptor mRNA, and did respond to exogenous bFGF; (b) androgen-insensitive, moderately metastatic DU 145 cells did produce measurable amounts of biologically active bFGF, expressed large amounts of FGF receptor mRNA, and responded to exogenous bFGF and the heparin-binding fractions from DU 145 cell extracts; (c) androgen-insensitive and highly metastatic PC 3 cells also produced measurable amounts of bFGF but did not demonstrate a growth response to either the heparin-binding fractions from PC 3 cell extracts or exogenous bFGF, even though large amounts of FGF receptor mRNA were expressed in PC 3 cells. These results suggest the possibility that differences in production of, and response to, bFGF may be associated with different biological behavior.

¹ This work was supported by the Whirlpool Foundation, Grants 90-44 and JFRA 304 from the American Cancer Society, and the Cancer and Urology Research Endowment Fund of the University of Chicago.

² To whom requests for reprints should be addressed, at Box 403, The University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637.

Received 8/ 6/91. Accepted 11/12/91.

This article has been cited by other articles:

				O. B. Goodman Jr., M. Febbraio, R. Simantov, R. Zheng, R. Shen, R. L. Silverstein, and D. M. Nanus Neprilysin Inhibits Angiogenesis via Proteolysis of Fibroblast Growth Factor-2 J. Biol. Chem., November 3, 2006; 281(44): 33597 - 33605. [Abstract] [Full Text] [PDF]

				M. Hatziapostolou, C. Polytarchou, P. Katsoris, J. Courty, and E. Papadimitriou Heparin Affin Regulatory Peptide/Pleiotrophin Mediates Fibroblast Growth Factor 2 Stimulatory Effects on Human Prostate Cancer Cells J. Biol. Chem., October 27, 2006; 281(43): 32217 - 32226. [Abstract] [Full Text] [PDF]

				T. Takeuchi, M. Suzuki, J. Kumagai, T. Kamijo, M. Sakai, and T. Kitamura Extracellular matrix dermatopontin modulates prostate cell growth in vivo. J. Endocrinol., August 1, 2006; 190(2): 351 - 361. [Abstract] [Full Text] [PDF]

				U. V. Wesley, M. McGroarty, and A. Homoyouni Dipeptidyl Peptidase Inhibits Malignant Phenotype of Prostate Cancer Cells by Blocking Basic Fibroblast Growth Factor Signaling Pathway Cancer Res., February 15, 2005; 65(4): 1325 - 1334. [Abstract] [Full Text] [PDF]

				C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]

				N. Blaszczyk, B. A. Masri, N. R. Mawji, T. Ueda, G. McAlinden, C. P. Duncan, N. Bruchovsky, H.-U. Schweikert, D. Schnabel, E. C. Jones, et al. Osteoblast-Derived Factors Induce Androgen-Independent Proliferation and Expression of Prostate-Specific Antigen in Human Prostate Cancer Cells Clin. Cancer Res., March 1, 2004; 10(5): 1860 - 1869. [Abstract] [Full Text] [PDF]

				H. Kuniyasu, R. Ukai, D. Johnston, P. Troncoso, I. J. Fidler, and C. A. Pettaway The Relative mRNA Expression Levels of Matrix Metalloproteinase to E-Cadherin in Prostate Biopsy Specimens Distinguishes Organ-confined from Advanced Prostate Cancer at Radical Prostatectomy Clin. Cancer Res., June 1, 2003; 9(6): 2185 - 2194. [Abstract] [Full Text] [PDF]

				H. Kubo, R. Cao, E. Brakenhielm, T. Makinen, Y. Cao, and K. Alitalo Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea PNAS, June 25, 2002; 99(13): 8868 - 8873. [Abstract] [Full Text] [PDF]

				X. Xu, E. Kreye, C. B. Kuo, and A. M. Walker A Molecular Mimic of Phosphorylated Prolactin Markedly Reduced Tumor Incidence and Size When DU145 Human Prostate Cancer Cells Were Grown in Nude Mice Cancer Res., August 1, 2001; 61(16): 6098 - 6104. [Abstract] [Full Text] [PDF]

				R. Giavazzi, R. Giuliani, D. Coltrini, M. R. Bani, C. Ferri, B. Sennino, M. P. M. Tosatti, A. Stoppacciaro, and M. Presta Modulation of Tumor Angiogenesis by Conditional Expression of Fibroblast Growth Factor-2 Affects Early but not Established Tumors Cancer Res., January 1, 2001; 61(1): 309 - 317. [Abstract] [Full Text]

				A. D. Laird, P. Vajkoczy, L. K. Shawver, A. Thurnher, C. Liang, M. Mohammadi, J. Schlessinger, A. Ullrich, S. R. Hubbard, R. A. Blake, et al. SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors Cancer Res., August 1, 2000; 60(15): 4152 - 4160. [Abstract] [Full Text]

				H. Kuniyasu, P. Troncoso, D. Johnston, C. D. Bucana, E. Tahara, I. J. Fidler, and C. A. Pettaway Relative Expression of Type IV Collagenase, E-cadherin, and Vascular Endothelial Growth Factor/Vascular Permeability Factor in Prostatectomy Specimens Distinguishes Organ-confined from Pathologically Advanced Prostate Cancers Clin. Cancer Res., June 1, 2000; 6(6): 2295 - 2308. [Abstract] [Full Text]

				K. Inoue, J. W. Slaton, B. Y. Eve, S. J. Kim, P. Perrotte, M. D. Balbay, S. Yano, M. Bar-Eli, R. Radinsky, C. A. Pettaway, et al. Interleukin 8 Expression Regulates Tumorigenicity and Metastases in Androgen-independent Prostate Cancer Clin. Cancer Res., May 1, 2000; 6(5): 2104 - 2119. [Abstract] [Full Text]

				D. NIE, K. TANG, K. SZEKERES, L. LI, and K. V. HONN Eicosanoid Regulation of Angiogenesis in Human Prostate Carcinoma and Its Therapeutic Implications Ann. N.Y. Acad. Sci., April 1, 2000; 905(1): 165 - 176. [Abstract] [Full Text] [PDF]

				M. A. Sortino, F. Condorelli, C. Vancheri, A. Chiarenza, R. Bernardini, U. Consoli, and P. L. Canonico Mitogenic Effect of Nerve Growth Factor (NGF) in LNCaP Prostate Adenocarcinoma Cells: Role of the High- and Low-Affinity NGF Receptors Mol. Endocrinol., January 1, 2000; 14(1): 124 - 136. [Abstract] [Full Text]

				D. Giri, F. Ropiquet, and M. Ittmann Alterations in Expression of Basic Fibroblast Growth Factor (FGF) 2 and Its Receptor FGFR-1 in Human Prostate Cancer Clin. Cancer Res., May 1, 1999; 5(5): 1063 - 1071. [Abstract] [Full Text] [PDF]

				J. A. Uria, M. Balbin, J. M. Lopez, J. Alvarez, F. Vizoso, M. Takigawa, and C. Lopez-Otin Collagenase-3 (MMP-13) Expression in Chondrosarcoma Cells and Its Regulation by Basic Fibroblast Growth Factor Am. J. Pathol., July 1, 1998; 153(1): 91 - 101. [Abstract] [Full Text] [PDF]

				P. J. Russell, S. Bennett, and P. Stricker Growth factor involvement in progression of prostate cancer Clin. Chem., April 1, 1998; 44(4): 705 - 723. [Abstract] [Full Text] [PDF]

				T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]

				C. Guillemette, E. Levesque, M. Beaulieu, D. Turgeon, D. W. Hum, and A. Belanger Differential Regulation of Two Uridine Diphospho-Glucuronosyltransferases, UGT2B15 and UGT2B17, in Human Prostate LNCaP Cells Endocrinology, July 1, 1997; 138(7): 2998 - 3005. [Abstract] [Full Text] [PDF]